{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Liu Y"],"funding":["Fundamental Research Funds for the Central Universities","the National Natural Science Foundation of China","Beijing Natural Science Foundation"],"pagination":["117"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12645685"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["18(1)"],"pubmed_abstract":["2-Hydroxy-3-methylvalerate (HMV), a kind of bioactive aliphatic 2-hydroxy acids, is a building block and a key intermediate for pharmaceuticals, including beauvericin, yet its microbial synthesis remains largely unexplored. Here, we present a synthetic biology strategy for high-titer production of HMV that couples mixed-sugar utilization with a division-of-labor microbial consortium. Co-feeding glucose and xylose synchronized substrate uptake with product formation, eliminating intermediate overflow and rerouting carbon from by-products into efficient HMV biosynthesis. To reduce the metabolic burden of the host, the HMV pathway is divided into two engineered strains: one optimized for glucose-to-intermediate conversion, the other for xylose-to-HMV completion. The best consortium, KMV-G-X, "],"journal":["Biotechnology for biofuels and bioproducts"],"pubmed_title":["Co-utilization of glucose and xylose in synthetic Escherichia coli consortia for efficient 2-hydroxy-3-methylvalerate biosynthesis."],"pmcid":["PMC12645685"],"funding_grant_id":["buctrc202341, JD2537","2252017","22578021, 22308018"],"pubmed_authors":["Liu Y","Wang S","Su H"],"additional_accession":[]},"is_claimable":false,"name":"Co-utilization of glucose and xylose in synthetic Escherichia coli consortia for efficient 2-hydroxy-3-methylvalerate biosynthesis.","description":"2-Hydroxy-3-methylvalerate (HMV), a kind of bioactive aliphatic 2-hydroxy acids, is a building block and a key intermediate for pharmaceuticals, including beauvericin, yet its microbial synthesis remains largely unexplored. Here, we present a synthetic biology strategy for high-titer production of HMV that couples mixed-sugar utilization with a division-of-labor microbial consortium. Co-feeding glucose and xylose synchronized substrate uptake with product formation, eliminating intermediate overflow and rerouting carbon from by-products into efficient HMV biosynthesis. To reduce the metabolic burden of the host, the HMV pathway is divided into two engineered strains: one optimized for glucose-to-intermediate conversion, the other for xylose-to-HMV completion. The best consortium, KMV-G-X, ","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Nov","modification":"2026-06-05T19:12:46.863Z","creation":"2026-05-20T03:14:49.066Z"},"accession":"S-EPMC12645685","cross_references":{"pubmed":["41291874"],"doi":["10.1186/s13068-025-02716-4"]}}